“The approval of Pluvicto offers new hope to the mCRPC community.” The recommended administration for 177Lu-PSMA-617 is 7.4 GBq (200 mCi) delivered intravenously every 6 weeks for up to 6 doses, or until disease progression or unacceptable toxicity occurs. References FDA approves Pluvic...
177Lu-PSMA-617 is approved by the FDA for the treatment of patients with PSMA-positive mCRPC in the post androgen receptor pathway inhibition, post taxane-based chemotherapy setting.2 The approval of LuPSMA was based on findings from the VISION trial, in which adding LuPSMA to SOC led to ...
part 1 of 2 korean j urol oncol, 18 (3) (2020), pp. 170-182 crossref google scholar 3 j. fallah, s. agrawal, h. gittleman, et al. fda approval summary: lutetium lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer clin cancer res, 29 (9)...
Results from the VISION trial (NCT03511664) led to the approval of lutetium-177 (177Lu)鈥揚SMA-617 for the treatment of metastatic castration-resistant pro... Mohamed E. Ahmed,Ahmad S. Abdelrazek,Geoffrey Johnson,... - Urologic Oncology: Seminars and Original Investigations 被引量: 0发表: ...
Approval was granted by the ethics committee of the Albert-Ludwigs-University Freiburg (Vote no.: 551/17). Informed consent was obtained from all individual participants included in the study. Consent for publication Patients signed informed consent regarding publishing their data. Competing interests ...
This initial experience may be biased by number of patients with limited standard of care options at the time of FDA approval of LuPSMA and could improve with better patient selection. However, this also highlights the continued need to develop novel therapeutic strategies for CRPC pts post-Lu...
During 177Lu–PSMA therapy, co-administration of ARPI occurred in 10/24 (23.8%) of patients.Conclusions:This study highlights the differences in quality metrics between patients who received 177Lu–PSMA therapy in a real-world practice setting compared to the FDA label for this agent and VISION...